Both in Diagnostics
Intellia Therapeutics vs Myriad Genetics
Over the past year NTLA returned −5.0% and MYGN returned −27.0%; their daily moves had a correlation of 0.25.
NTLA −5.0% MYGN −27.0%Growth of $1, one year, split-adjusted
| Metric | NTLA | MYGN |
|---|---|---|
| Price | $12.42 | $5.97 |
| Market cap | $1.74B | $571.0M |
| Today | +4.68% | −1.16% |
| 1 month | +0.4% | +39.5% |
| 6 months | −10.4% | +45.3% |
| Year to date | +38.1% | −2.9% |
| 1 year | −5.0% | −27.0% |
| Revenue growth (YoY) | −46.2% | −10.5% |
| Gross margin | 100.0% | 66.6% |
| Net margin | −1392.3% | −22.7% |
| P/E (TTM) | — | — |
| Price / sales | 29.2× | 0.7× |
| Net cash | $437.8M | -$5.5M |
| Dividend yield | — | — |
| Volatility (60d) | 63.3% | 85.1% |
| Short % of float | 38.6% | 10.1% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).